Antares Pharma Inc

Most Recent

  • uploads///Graph
    Company & Industry Overviews

    Makena Auto Injector Is a Key Asset for Antares Pharma in 2018

    In H1 2018, Antares Pharma (ATRS) reported revenues of $6.7 million from its Makena product.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Antares Pharma Is Expected to Report Positive EPS in 2019

    In H1 2018, Antares Pharma (ATRS) reported a loss per share of $0.07, which was higher by $0.02 on a year-over-year (or YoY) basis.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Antares Pharma Could Report Solid Revenue Growth in Fiscal 2018

    In H1 2018, Antares Pharma (ATRS) reported revenues of $26.86 million, which was a year-over-year (or YoY) rise of 6%.

    By Margaret Patrick
  • uploads///syringe _
    Company & Industry Overviews

    Here’s Why Antares Pharma Stock Rose on October 2

    Antares Pharma (ATRS) rose a solid 15.64% from $3.26 on October 1 to $3.77 on October 2.

    By Margaret Patrick
  • uploads///Amag key products
    Company & Industry Overviews

    Label Expansion of Ferahame Bodes Well for AMAG Pharmaceuticals

    AMAG’s revenues from Ferahame grew at a higher pace to $26 million in 3Q17 from $22.2 million in 3Q16.

    By Kenneth Smith
  • uploads///Antares Pharmas pipeline
    Company & Industry Overviews

    Antares Pharma’s Sale of ZomaJet to Ferring Pharmaceuticals

    ZomaJet is Antares Pharma’s needle-free autoinjector, which is designed to deliver human growth hormone (or HGH) treatment to children with growth retardation.

    By Kenneth Smith
  • uploads///XYOSTED Profile
    Company & Industry Overviews

    Exploring Antares Pharma’s Current Pipeline of Products

    On October 11, 2017, Antares Pharma (ATRS) was notified by the FDA that it had found deficiencies in Xyosted.

    By Kenneth Smith
  • uploads///Sumatriptan market share growth
    Company & Industry Overviews

    Which Products Are Driving Revenues for Antares Pharma in 2017?

    Sumatriptan is the only injectable triptan approved for use in the US. The product achieved a market share of 26.0% in 2Q17, up from 21.0% in 1Q17.

    By Kenneth Smith
  • uploads///Antares Analyst Estimates
    Company & Industry Overviews

    Analysts’ Recommendations for Antares Pharma in November 2017

    Antares Pharma’s (ATRS) products include Vibex, a pressure-assisted autoinjector. The global injectable drug delivery market is expected to grow to $624.5 billion by 2021.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.